Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3009 alone or in combination for extensive-stage small cell lung cancer
2025-523972-21-00Phase 2Completed
- Sponsor
- Fortvita Biologics
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2 trial of IBI3009 in small cell lung cancer (SCLC) (2 arms), sponsored by Fortvita Biologics. Started Apr 2026; status: completed.
02
Drugs
IBI3009
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2025-523972-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523972-21-00.